Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics Inc (NQ: ATOS )

0.8200 +0.0077 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 354,912
Open 0.8200
Bid (Size) 0.8050 (113)
Ask (Size) 0.8200 (74)
Prev. Close 0.8123
Today's Range 0.7936 - 0.8399
52wk Range 0.5000 - 1.620
Shares Outstanding 126,624,110
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 3 Best Biotech Stocks Under $1 to Buy for January
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 49 companies made new 52-week lows. 
Via Benzinga

Performance

YTD
+39.88%
+39.88%
1 Month
+57.21%
+57.21%
3 Month
-16.77%
-16.77%
6 Month
-11.17%
-11.17%
1 Year
-33.87%
-33.87%

More News

Read More
Recap: Atossa Therapeutics Q2 Earnings
Via Benzinga
Why Is NuZee Down By Over 21%: Here Are 38 Stocks Moving Premarket
Via Benzinga
20 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
61 Biggest Movers From Yesterday
Via Benzinga
Analyzing Atossa Therapeutics's Unusual Options Activity
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ATOS Stock Holders Should Mark Their Calendars for Oct. 7
Via InvestorPlace
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden
Via Benzinga
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress
Via InvestorPlace
Atossa Therapeutics Has a Steep Climb Ahead of It
Via InvestorPlace
Exposures COVID-19
As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock
Via InvestorPlace
Exposures COVID-19
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
Via InvestorPlace
With Zero Revenue, I Can’t Get Excited About Atossa
Via InvestorPlace
Exposures COVID-19
88 Biggest Movers From Yesterday
Via Benzinga
The Bear Case for Atossa Therapeutics Makes More Sense at This Time
Via InvestorPlace
Most Active Equity Options For Midday - Wednesday, Aug. 4
Via Talk Markets
Investors Should Avoid High-Risk Atossa Therapeutics
Via InvestorPlace
The Week In Charts: Trading Stuff Part 3 - Trading (Or Not Trading!) OGRes, Russian Dolls, ETFs
Via Talk Markets
63 Biggest Movers From Friday
Via Benzinga
Exposures Product Safety
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.